They showed that TSPO knockdown increased malignancy in vitro, whereas its agonist FGIN‐1‐27 reduced tumor growth in vivo, suggesting that targeting TSPO could be beneficial in CRC treatment [36]. This evidence concerns the gene TSPO and neoplasm.